心血管-肾脏-代谢综合征（CKM）：从跨器官机制到综合管理的研究进展
司冯源

石河子大学公共卫生学院，新疆石河子市，832003；

摘要：心血管-肾脏-代谢综合征（cardiovascular-kidney-metabolic syndrome，CKM）并不是在传统代谢综合征基础上简单增加一个器官名称，而是试图把肥胖、糖脂代谢异常、慢性肾脏病和心血管结局放在同一条疾病链条中理解。近年来，美国心脏协会提出CKM健康框架后，尿白蛋白/肌酐比、估算肾小球滤过率、心力衰竭风险以及社会决定因素等内容被更早地纳入心血管预防视野。本文围绕“上游脂肪异常—代谢紊乱—肾脏损伤—心血管事件”的演进路径，对CKM的流行病学负担、心肾代谢互作机制、临床分期、筛查评估与综合管理策略进行综述。

关键词：心血管-肾脏-代谢综合征；慢性肾脏病；代谢异常；心力衰竭；综合管理

参考文献

[1] Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. doi:10.1161/CIR.0000000000001184.

[2] Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001186.

[3] Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 2024;331(21):1858-1860. doi:10.1001/jama.2024.6892.

[4] He D, Zhang X, Li C, Yang C, Yu M, Wang J, et al. Rising Prevalence of Cardiovascular-Kidney-Metabolic Syndrome in China, 2010-2019: National Cross-Sectional Surveys. J Am Coll Cardiol. 2025;86(3):213-216. doi:10.1016/j.jacc.2025.05.030.

[5] Zhu R, Wang R, He J, et al. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health. JAMA Netw Open. 2024;7(11):e2445309. doi:10.1001/jamanetworkopen.2024.45309.

[6] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018.

[7] The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-127. doi:10.1056/NEJMoa2204233.

[8] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563.

[9] FLOW Trial Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109-121.

[10] Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-484.

[11] Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the PREVENT Equations. Circulation. 2024;149:430-449.

[12] Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health. Circulation. 2022;146:e18-e43.